| 000 | 01830 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517110701.0 | ||
| 264 | 0 | _c20171222 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdw262 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDieci, M V | |
| 245 | 0 | 0 |
_aIntegrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _c10 2016 |
||
| 300 |
_a1867-73 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBiopsy, Large-Core Needle |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLapatinib |
| 650 | 0 | 4 |
_aLymphocytes, Tumor-Infiltrating _ximmunology |
| 650 | 0 | 4 | _aMicroarray Analysis |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoadjuvant Therapy |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aQuinazolines _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptors, Estrogen _xgenetics |
| 650 | 0 | 4 |
_aTrastuzumab _xadministration & dosage |
| 700 | 1 | _aPrat, A | |
| 700 | 1 | _aTagliafico, E | |
| 700 | 1 | _aParé, L | |
| 700 | 1 | _aFicarra, G | |
| 700 | 1 | _aBisagni, G | |
| 700 | 1 | _aPiacentini, F | |
| 700 | 1 | _aGenerali, D G | |
| 700 | 1 | _aConte, P | |
| 700 | 1 | _aGuarneri, V | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 27 _gno. 10 _gp. 1867-73 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdw262 _zAvailable from publisher's website |
| 999 |
_c26291069 _d26291069 |
||